share_log

JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $15

Benzinga ·  May 7 23:29

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the price target from $14 to $15.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment